Amgen's gastric cancer drug improves survival in phase 3 trial

Amgen announced its Phase 3 FORTITUDE-101 clinical trial for bemarituzumab met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in overall survival for patients with FGFR2b-overexpressing gastric or gastroesophageal junction cancer, addressing a significant unmet medical need. This positive development for a key oncology asset reinforces Amgen's strong financial health, characterized by a 69% gross profit margin and 15.6% revenue growth, with analysts projecting continued net income growth and an undervalued stock. The company is also progressing its obesity treatment candidate, MariTide, into Phase 3, despite noted competitive pressures in that market.

Analysis

Amgen (AMGN) has reported a significant clinical success with its Phase 3 FORTITUDE-101 trial for bemarituzumab, which met its primary endpoint of improving overall survival in patients with FGFR2b-overexpressing gastric cancer. This positive result for a key oncology pipeline asset is particularly meaningful given that gastric cancer is the fifth leading cause of cancer-related deaths globally with limited treatment options. Financially, this development is backed by Amgen's strong fundamentals, including a 69% gross profit margin and 15.6% revenue growth over the last year, with analysts projecting continued net income growth. While the trial was successful, it is important to note the higher frequency and severity of ocular adverse events in the bemarituzumab arm, which will be a key detail for regulators and clinicians. The company’s pipeline is further diversified by its obesity candidate, MariTide, which demonstrated up to 20% average weight loss in a Phase 2 study and is now advancing to a Phase 3 program, though it faces a competitive market. Analyst sentiment, exemplified by Piper Sandler's maintained Overweight rating and $328 price target, remains positive, citing strong volume growth from existing products like Repatha and Tezspire, reinforcing the company's solid commercial execution alongside its R&D progress.

Key Decisions for Investors

• The positive Phase 3 data for bemarituzumab significantly de-risks a key late-stage asset in a high-unmet-need oncology market, supporting a bullish outlook on Amgen's long-term growth profile.
• Investors should closely monitor the full data presentation from the FORTITUDE-101 trial, paying specific attention to the safety profile and management of ocular adverse events, as this will be critical for determining the drug's commercial potential and market adoption.
• Given the company's strong financial health, including 15.6% revenue growth and a 69% gross margin, coupled with analyst views that the stock is undervalued, the current valuation may represent an attractive entry point for those confident in the late-stage pipeline.
• While the MariTide obesity data is promising, investors should temper expectations due to the highly competitive landscape and view its progress as a source of potential upside rather than a core valuation driver until Phase 3 data and a clear market strategy emerge.